**8. Future perspectives and conclusion**

The future of gene signature-based drug repositioning is bright. The booming biotechnology and pharmaceutical industry, especially the emerging sequencing and MS field, supplies an important motivation to sequence more omics data related to drugs and diseases. The artificial intelligence industry, particularly the deep learning algorithm, will also promote the rapid development of the drug repositioning field as it will improve the rate of the true positives and lower the rate of false positives. The omics data of drugs and diseases is like electricity, while the algorithm is like a machine. The seamless combinations of them will produce new opportunities for gene signature-based drug repositioning. More data means a larger searchable space to identify the new relationship between drugs and diseases. Additionally, the signatures-based combination of drugs could also be investigated to deal with intractable diseases. Meanwhile, more evidence from different aspects of the drug-disease pairs will improve the quality of perdition.

In the end, we highlight the key points of this chapter.

